Amicus Therapeutics Inc. (FOLD) Trading Down 1.4%
Shares of Amicus Therapeutics Inc. (NASDAQ:FOLD) fell 1.4% during trading on Wednesday . The stock traded as low as $7.63 and last traded at $7.78, with a volume of 1,310,151 shares trading hands. The stock had previously closed at $7.89.
Several research firms have recently commented on FOLD. Zacks Investment Research downgraded shares of Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, August 11th. Chardan Capital set a $15.00 price objective on shares of Amicus Therapeutics and gave the company a “buy” rating in a report on Thursday, August 11th. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $19.00 price objective (up from $17.00) on shares of Amicus Therapeutics in a report on Tuesday, June 14th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $12.19.
The company’s market cap is $1.13 billion. The stock’s 50-day moving average is $6.99 and its 200-day moving average is $6.96.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/amicus-therapeutics-inc-fold-trading-down-1-4.html
Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by $0.07. On average, analysts predict that Amicus Therapeutics Inc. will post ($1.35) EPS for the current year.
In other Amicus Therapeutics news, insider Jay Barth sold 10,458 shares of the firm’s stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $7.00, for a total transaction of $73,206.00. Following the sale, the insider now owns 15,000 shares of the company’s stock, valued at $105,000. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Perceptive Advisors Llc sold 1,100,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 25th. The stock was sold at an average price of $6.81, for a total transaction of $7,491,000.00. The disclosure for this sale can be found here. Company insiders own 3.40% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the company. Teachers Advisors Inc. boosted its position in shares of Amicus Therapeutics by 1.0% in the first quarter. Teachers Advisors Inc. now owns 173,294 shares of the biopharmaceutical company’s stock worth $1,464,000 after buying an additional 1,750 shares during the last quarter. Principal Financial Group Inc. boosted its position in shares of Amicus Therapeutics by 10.5% in the second quarter. Principal Financial Group Inc. now owns 22,411 shares of the biopharmaceutical company’s stock worth $122,000 after buying an additional 2,122 shares during the last quarter. BlackRock Group LTD boosted its position in shares of Amicus Therapeutics by 3.9% in the second quarter. BlackRock Group LTD now owns 72,024 shares of the biopharmaceutical company’s stock worth $393,000 after buying an additional 2,681 shares during the last quarter. ProShare Advisors LLC boosted its position in shares of Amicus Therapeutics by 3.1% in the second quarter. ProShare Advisors LLC now owns 110,154 shares of the biopharmaceutical company’s stock worth $601,000 after buying an additional 3,291 shares during the last quarter. Finally, Legal & General Group Plc boosted its position in shares of Amicus Therapeutics by 14.4% in the first quarter. Legal & General Group Plc now owns 29,770 shares of the biopharmaceutical company’s stock worth $244,000 after buying an additional 3,743 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.